Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Spring;9(2):189-193.
doi: 10.22088/cjim.9.2.189.

Jak-2 mutation frequency in patients with thrombocytosis

Osman Yokus  1 , Habip Gedik  2
Affiliations

Jak-2 mutation frequency in patients with thrombocytosis

Osman Yokus et al. Caspian J Intern Med. 2018 Spring.

Abstract

Background: We aimed to investigate the etiologic causes and the existence of Janus kinase 2 mutation (JAK2) in cases with thrombocytosis.

Methods: In this retrospective study, patients who were admitted to hematology clinic with thrombocytosis between 2013 and 2015 were investigated in terms of the etiological causes of thrombocytosis and the existence of JAK2 mutation.

Results: We retrospectively evaluated 136 cases that underwent JAK2 mutation analysis due to ET preliminary diagnosis in our hematology clinic. The mean age of the patients was 56.7±15.3 years (range: 22-86 years) and 71 (52%) were males. JAK2 mutation was found to be positive in 58 (42%) of cases. The mean platelet counts of the cases were 860.25×109 / L (range: 455-1,105 109 /L) and the mean spleen vertical length was 135.1±21.6 mm (range: 110-220 mm).

Conclusions: JAK2 mutation analysis and bone marrow biopsy are the two main procedures to diagnose primary thrombocytosis in adults with persistent thrombocytosis after excluding the causes of secondary thrombocytosis. Myeloproliferative neoplasms and essential thrombocytosis are the common causes of primary thrombocytosis in adults with persistent thrombocytosis, as myelodysplastic syndrome rarely causes primary thrombocytosis.

Keywords: Essential thrombocytosis; Janus kinase 2; Thrombocytosis.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest in this study.

References

    1. Mitus AJ, Schafer AI. Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am. 1990;4:157–78. - PubMed
    1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5. - PubMed
    1. Schafer AI. Essential thrombocythemia and thrombocytosis. In: Lichtman MA, Beutler E, Kipps TJ, editors. Williams hematology. 7th ed. New York: McGraw-Hill Co ; 2006. pp. 1785–94.
    1. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111:1686–9. - PubMed
    1. Lichtman MA. Idiopathic myelofibrosis (Myelofibrosis with myeloid metaplasia) In: LichtmanMA , Beutler E, Kipps TJ, editors. Williams’s hematology. 7th ed. New York: McGraw-Hill ; 2006. pp. 1295–313.

LinkOut - more resources